Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of CPX-351 in Newly Diagnosed AML at High Risk for Induction Mortality
NCT02286726Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2015
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of daunorubicin + cytarabine liposome in acute myeloid leukemia (AML) (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Number of Participants With a Response at 8 weeks. Started May 2015; status: completed.
02
Drugs
daunorubicin + cytarabine liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02286726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02286726.